Question 1

What is the difference between Mounjaro and Zepbound?

Accepted Answer

Mounjaro and Zepbound are the same molecule — tirzepatide — made by the same manufacturer, Eli Lilly. The difference is what the FDA label says and how insurance treats them. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with a comorbidity, and also for moderate-to-severe obstructive sleep apnea in adults with obesity. The dose range (2.5-15 mg weekly) and once-weekly injection schedule are identical. Which label you get depends on your diagnosis. Insurance coverage, prior-authorization rules, and copays can differ sharply between the two.

Question 2

Which causes more weight loss, Mounjaro or Zepbound?

Accepted Answer

On a head-to-head basis at matched doses, they produce identical weight loss — same molecule, same concentrations, same injection. The differences you see in published trials are because they were studied in different patient populations. Zepbound was studied in adults with obesity without diabetes (SURMOUNT-1: 22.5% mean weight loss at 15 mg over 72 weeks). Mounjaro was studied in people with type 2 diabetes (SURPASS program: smaller absolute weight reductions, typically 10-12 kg). Patients with type 2 diabetes generally lose less weight on any GLP-1 than those without diabetes. The drug is the same; the trial populations were not.

Question 3

Can I switch between Mounjaro and Zepbound?

Accepted Answer

Clinically, switching is trivial because the active ingredient is the same — no washout period is needed and no dose conversion is required. You can stay on your current dose and simply change the label. The real reason to switch is usually insurance or diagnosis. If you were prescribed Mounjaro for diabetes and later develop obesity as a coverable indication, your prescriber might move you to Zepbound. If you were on Zepbound for weight and develop type 2 diabetes, Mounjaro might open up better coverage. Any switch should be handled through your prescriber and your insurance plan.

Question 4

Which has fewer side effects, Mounjaro or Zepbound?

Accepted Answer

Side-effect profiles are essentially identical because the drug is the same. The reason Zepbound's trial numbers look worse (nausea 24-33% versus Mounjaro 12-18%) is that Zepbound was studied at top weight-loss doses in patients without diabetes, while Mounjaro was studied at diabetes doses. At the same milligram dose in the same patient, you would expect the same tolerability. Both carry the same thyroid-tumor boxed warning. Both can cause pancreatitis and gallbladder events rarely. Slow titration helps in both cases. Your experience depends far more on your own biology and the pace of titration than on which label you are on.

Question 5

Is Mounjaro or Zepbound cheaper?

Accepted Answer

Sticker prices are similar because the drug and manufacturer are identical. What you actually pay depends entirely on insurance and indication. Mounjaro is covered by most commercial plans and Medicare Part D for type 2 diabetes, with typical copays of $25-$150 a month on preferred tiers. Zepbound coverage is more restrictive — many plans exclude weight-loss medications entirely, and Medicare Part D does not cover it for weight loss alone under federal law. For self-pay, Eli Lilly launched Zepbound vials through LillyDirect in December 2025 at lower monthly prices than the pen. Check your specific plan's formulary and prior-authorization rules.

Question 6

Are Mounjaro and Zepbound the same drug?

Accepted Answer

Yes, the active ingredient is identical — tirzepatide — and both are made by Eli Lilly. What differs is the FDA label and the insurance treatment. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management and obstructive sleep apnea. The dose range, injection schedule, and pen device are the same. Because the label governs how insurance classifies the prescription, your pharmacy benefit processes them as different products even though the drug in the pen is the same. Patients should never try to use one interchangeably with the other off-label — your prescribed label should match your diagnosed condition.

Question 7

Do Mounjaro and Zepbound work the same way in the body?

Accepted Answer

Yes. Both are tirzepatide, a dual agonist that activates two incretin receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Activating both pathways enhances insulin secretion when blood sugar is elevated, suppresses glucagon, slows gastric emptying, and reduces appetite through central mechanisms. The effects on blood sugar, weight, and gut function are identical at identical doses. That is why patients with both type 2 diabetes and obesity often benefit from tirzepatide regardless of which label their prescription carries — the underlying biology is one drug. Your clinician picks the label that best matches your diagnosis and coverage.

Question 8

Can I take either Mounjaro or Zepbound for weight loss?

Accepted Answer

Only Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight with a weight-related comorbidity. Mounjaro is approved only for type 2 diabetes. Taking Mounjaro off-label for weight loss is generally not covered by insurance, and prescribers are increasingly reluctant to write off-label prescriptions when a labeled alternative exists. If weight management is your primary goal and you do not have type 2 diabetes, Zepbound is the appropriate label. If you have both conditions, your prescriber can choose based on the primary treatment goal and your insurance coverage. Always match the label to the diagnosis.

Question 9

Why does Eli Lilly sell the same molecule under two different names?

Accepted Answer

The two-brand approach is standard in the GLP-1 industry — Novo Nordisk does the same with Ozempic (diabetes) and Wegovy (weight management), both containing semaglutide. Separate labels allow each indication to be studied in its own FDA-required trials, packaged with indication-specific dosing guidance, and priced and covered separately by insurance. It also lets manufacturers set different list prices and savings programs for each market. For patients, the key takeaway is that the pen contains the same tirzepatide — the brand name on the label reflects the approved use, not any difference in drug substance or manufacturing.

Feature	Mounjaro(tirzepatide)	Zepbound(tirzepatide)
Active Ingredient	tirzepatide	tirzepatide
Drug Class	Dual GIP and GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Eli Lilly	Eli Lilly
FDA Approved	2022-05-13	2023-11-08
Approved Indications	Type 2 diabetes mellitus (adjunct to diet and exercise)	Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity (adjunct to diet and exercise) Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024)
Route	subcutaneous injection	subcutaneous injection
Frequency	Once weekly	Once weekly
Starting Dose	2.5 mg weekly	2.5 mg weekly
Maintenance Dose	5 mg, 10 mg, or 15 mg weekly	5 mg, 10 mg, or 15 mg weekly
Max Dose	15 mg weekly	15 mg weekly
Weight Loss (%)	22.5%	22.5%
A1C Reduction	2.4%	N/A (not indicated for diabetes)
Key Trial	SURMOUNT-1 (72 weeks)	SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks)
List Price	$1,023-$1,176/month	$1,060-$1,176/month
With Insurance	$25-$150/month (varies by plan)	$25-$250/month (varies; weight-loss coverage is limited)
Savings Card	$25/month (Lilly savings card, commercially insured)	$25/month (Lilly savings card, commercially insured)

Side Effect	Mounjaro	Zepbound
Nausea	12-18%	24-33%
Diarrhea	12-17%	18-25%
Decreased appetite	5-11%	Not reported
Vomiting	5-9%	10-18%
Constipation	6-7%	13-17%
Dyspepsia	5-8%	7-10%
Abdominal pain	5-6%	10-14%
Injection site reaction	3-5%	3-7%
Pancreatitis (rare)	<0.5%	<1%
Hair loss	Not reported	5-6%
Gallbladder events	Not reported	1.6%

Mounjaro vs Zepbound

Summary

Mounjaro vs Zepbound: Full Comparison

Side Effects: Mounjaro vs Zepbound

Related Comparisons

Frequently Asked Questions

Sources & References

FDA & Regulatory

Clinical Trial Records

Peer-Reviewed Literature

Safety Communications

Manufacturer Information

Professional Guidelines

Reference Entries

Additional References